PART I . Overview We are a clinical stage biotechnology company fully dedicated to developing IL-1-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1 monoclonal antibody (mAb) is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. Our current focus is on completing the Phase 2 (LO...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001534120-26-000011 | EDGAR | 102K words |
| 2025-03-20 | 2024-12-31 | 0001628280-25-013986 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001628280-24-013786 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001628280-23-009630 | EDGAR | — |
| 2022-03-02 | 2021-12-31 | 0001628280-22-004671 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001628280-21-004162 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001628280-20-003395 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001628280-19-003078 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001628280-18-003890 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001628280-17-002566 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001534120-25-000018 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038575 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001628280-25-024436 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-045965 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001628280-24-036591 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001628280-24-022763 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038036 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001628280-23-026990 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015703 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001628280-22-028538 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020866 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001628280-22-012436 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001534120-26-000016 | EDGAR | 1K words |
| 2026-03-23 | 0001534120-26-000010 | EDGAR | — |
| 2026-01-12 | 0001534120-26-000003 | EDGAR | — |
| 2025-12-02 | 0001534120-25-000022 | EDGAR | — |
| 2025-11-06 | 0001534120-25-000017 | EDGAR | — |
| 2025-10-29 | 0001534120-25-000013 | EDGAR | — |
| 2025-10-10 | 0001534120-25-000011 | EDGAR | — |
| 2025-10-01 | 0001534120-25-000009 | EDGAR | — |
| 2025-09-22 | 0001534120-25-000005 | EDGAR | — |
| 2025-08-07 | 0001628280-25-038570 | EDGAR | — |
284 total filings indexed. 252 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001534120 |
| Ticker | AVTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.avalotx.com |
| Listed | 2015-11-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report